Explaining the unexplainable: EGFR antibodies in colorectal cancer

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1735-1737

  Grothey, Axel ^a,b   Lenz, Heinz Josef ^a,b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; FOLINATE CALCIUM; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; EDITORIAL; HUMAN; MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84863993927     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.4194     Document Type: Editorial

References (21)

1. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
3. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
4. Van Cutsem E, Láng I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:5s, 2008 (suppl 15s; abstr 2)
5. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
6. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
7. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
8. Grothey A: EGFR antibodies in colorectal cancer: Where do they belong? J Clin Oncol 28:4668-4670, 2010
9. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
10. Seymour MT, Brown S, Richman S, et al: Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a large randomised trial with prospective molecular stratification. Eur J Cancer 47:S393 (suppl 1), 2011
11. Alberts SR, Sargent DJ, Smyrk TC, et al: Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG intergroup phase III trial N0147. J Clin Oncol 28:959s, 2010 (suppl; abstr CRA3507)
12. Goldberg RM, Sargent DJ, Thibodeau SN, et al: Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG intergroup phase III trial N0147. J Clin Oncol 28:262s, 2010 (suppl; abstr 3508)
13. Tveit KM, Guren T, Glimelius B, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30:1755-1762, 2012
14. Harstrick A, Gonzales A, Schleucher N, et al: Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: Biochemical mechanism of resistance. Anticancer Drugs 9:625-634, 1998 (Pubitemid 28420060)
15. Skvortsov S, Sarg B, Lindner H, et al: Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clin Appl 2:908-914, 2008 (Pubitemid 351943771)
16. Bijnsdorp IV, Kruyt FA, Fukushima M, et al: Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines. Cancer Sci 101:440-447, 2010
17. Kim HP, Yoon YK, Kim JW, et al: Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 4:e5933, 2009
18. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003 (Pubitemid 46606353)
19. Zhang W, El-Khoueiry A, Yang D, et al: K-ras mutation status associated with clinical outcome in metastatic colorectal cancer patients treated with 5-fluorouracil/oxaliplatin. Presented at the Gastrointestinal Cancers Symposium, Orlando, FL, January 15-17, 2009 (abstr 340)
20. Ratner ES, Keane FK, Lindner R, et al: A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 10.1038/onc.2011.539 [epub ahead of print on December 5, 2011]
21. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009